Abbott FDA Device Footprint: Diagnostics, Recalls & PMA Portfolio
A data-driven regulatory profile of Abbott's FDA clearances, PMA approvals, safety recalls, diagnostics division, and global manufacturing hubs in Illinois, California, Germany, and the Netherlands.
Executive Summary
What does the FDA database reveal about Abbott's medical device clearances, recalls, and manufacturing footprint?
Abbott holds a balanced regulatory portfolio divided between high-volume clinical chemistry diagnostics and high-risk cardiovascular devices. According to computed aggregates from official FDA databases, Abbott holds 1,218 active 510(k) clearances, 5,617 Premarket Approval (PMA) filings and supplements, and 909 associated recalls. The company's 510(k) clearances are concentrated in the Clinical Chemistry (420 clearances, or 34.5%) and Cardiovascular (166 clearances, or 13.6%) specialties, followed by General Hospital (160 clearances, or 13.1%), led by infusion pumps (product code FRN, 69 clearances), intravascular administration sets (product code FPA, 31 clearances), over-the-counter blood glucose test systems (product code NBW, 31 clearances), hematology cell counters (product code GKZ, 30 clearances), and catheter guide wires (product code DQX, 25 clearances). In the high-risk PMA sector, Abbott's portfolio is focused on cardiac rhythm management and diagnostic assays, led by automatic implantable cardioverter defibrillators with cardiac resynchronization (product code NIK, 489 filings), permanent pulse generators (product code NVZ, 385 filings), implantable cardioverter defibrillators (product code LWS, 355 filings), hepatitis B diagnostic assays (product code LOM, 293 filings), and ventricular bypass assist devices (product code DSQ, 275 filings).
This footprint is accompanied by 909 FDA-registered recalls, with gastrointestinal tubes (product code KNT, 84 recalls), clinical chemistry analyzers (product code JJE, 74 recalls), and hematology cell counters (product code GKZ, 52 recalls) representing the highest recall frequencies. Geographically, Abbott operates a global manufacturing and logistics footprint, with leading registered manufacturing hubs located in Lake Forest, Illinois (436 listings), Wiesbaden, Germany (264 listings), Temecula, California (131 listings), Sylmar, California (124 listings), and Heerlen, Netherlands (116 listings).
Abbott FDA Footprint at a Glance
- 510(k) clearances: 1,218 (Clinical Chemistry 420 / Cardiovascular 166 / General Hospital 160)
- PMA approvals and supplements: 5,617 (led by CRT-D defibrillators NIK — 489, pulse generators NVZ — 385, hepatitis assays LOM — 293, ventricular assist systems DSQ — 275)
- FDA-registered recalls: 909 (led by GI tubes KNT — 84, chemistry analyzers JJE — 74, hematology cell counters GKZ — 52)
- Establishment / device listings: 2,393 (Lake Forest, Wiesbaden, Temecula, Sylmar, and Heerlen lead)
- Defining 2025–2026 events: Early 2026 Class I sensor recall of FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems; October 2025 Class I recall of TactiFlex sensor-enabled ablation catheters
- Peer comparison position: Leader in diagnostic assay clearances (Clinical Chemistry) and ventricular assist system registrations among major medical device manufacturers
Introduction: The Balanced Profile of Abbott
Abbott is a global healthcare leader with a diverse portfolio spanning diagnostics, medical devices, nutritionals, and established pharmaceuticals. Within its medical technology business, Abbott is uniquely positioned: it is both a major provider of laboratory diagnostics instruments and assays (via its Diagnostics division, which includes Core Diagnostics, Molecular Diagnostics, Point of Care, and Rapid Diagnostics) and a leading manufacturer of implantable cardiac and vascular systems (via its Medical Devices division, which includes Cardiac Rhythm Management, Electrophysiology, Heart Failure, Neuromodulation, Structural Heart, and Vascular).
For hospital procurement teams, laboratory directors, and regulatory affairs managers, Abbott is a primary partner. The dual nature of its business means that its regulatory footprint must be analyzed through two distinct lenses: high-volume diagnostic assay clearances that navigate the 510(k) and clinical chemistry channels, and high-risk implantable therapeutic systems (such as pacemakers, defibrillators, and left ventricular assist devices) that go through the PMA process.
This report analyzes Abbott's active 510(k) clearances, Premarket Approval (PMA) history, product recalls, and international manufacturing registrations. Using computed aggregates from the official FDA databases, we detail the specific product codes, clinical trends, and global supply chain sites that shape Abbott's regulatory profile.
How These Numbers Were Computed
The figures in this dossier are aggregates computed from four public FDA datasets extracted in June 2026: the 510(k) database, the PMA database, the medical device recalls database, and the Establishment Registration and Device Listing database. Counts are produced by grouping records under Abbott's brand and its registered medical-device and diagnostic subsidiaries — for Abbott this includes its core divisions and major historical acquisitions (such as St. Jude Medical, Alere, Thoratec, and legacy Hospira/infusion pump lines) that operate under the corporate umbrella. Because legacy submissions often retain their original applicant name, clearances are counted across those entity names, while current establishment listings are attributed to the operating Abbott facilities that hold them today. Raw recall counts are reported as filed and should always be read against installed base: a company with a larger fleet of complex laboratory analyzers and automated glucose monitors will generate more field notices than a niche supplier, so recall count is a function of scale, not a simple quality verdict. This methodology is the same one applied across our peer company profiles so the numbers are directly comparable.
Key Historical Milestones and M&A Impact
Abbott's current regulatory footprint represents the combination of its traditional in-vitro diagnostics business with massive acquisitions in cardiovascular support, cardiac rhythm management, and rapid testing. The table below charts key milestones and acquisitions that have directly shaped Abbott's database profiles:
| Milestone / Acquisition | Year | Clinical Segment | Regulatory Significance |
|---|---|---|---|
| Diagnostics Division Expansion | 1970s | Lab Diagnostics | Established the foundation of Core Diagnostics, developing high-throughput chemistry and immunoassay clearings. |
| Hospira Spin-off | 2004 | Infusion / General Hosp. | Spun off Hospira's hospital products, though Abbott retained legacy infusion pump clearances (product code FRN) and nutritional devices. |
| Thoratec Acquisition ($3.4B) | 2015 | Heart Failure | Brought Thoratec's Left Ventricular Assist Devices (LVADs), introducing high-risk ventricular assist bypass PMAs (product code DSQ). |
| St. Jude Medical Acquisition ($25B) | 2017 | CRM & Electrophysiology | One of Abbott's largest acquisitions. Absorbed St. Jude's pacemakers, ICDs, and mapping tools, adding a massive CRM PMA supplement footprint (product code NIK). |
| Alere Acquisition ($5.3B) | 2017 | Rapid Diagnostics | Expanded point-of-care and rapid testing registrations, adding toxicology and lateral flow assays. |
| FreeStyle Libre Milestones | 2017+ | Diabetes Care | Continuous updates for continuous glucose monitoring (CGM) cleared under the OTC blood glucose pathway (product code NBW). |
| CardioMEMS Expansion | 2022 | Heart Failure | Expanded listings for implantable pulmonary artery pressure sensors to monitor heart failure patients remotely. |
| Wiesbaden Capacity Updates | 2025 | Diagnostics | Upgraded German manufacturing facilities to meet European IVDR requirements, adjusting active listings. |
The 510(k) Clearance Portfolio: Clinical Chemistry and Diagnostics Dominance
As of June 2026, Abbott holds 1,218 active 510(k) clearances. Segmenting these clearances by FDA medical specialty reveals a portfolio heavily weighted toward clinical laboratory diagnostics, reflecting their market leadership in hospital lab systems:
| Medical Specialty | Clearance Count | Percentage of 510(k) Portfolio | Core Technologies |
|---|---|---|---|
| Clinical Chemistry | 420 | 34.5% | Diagnostic assays (enzymes, proteins, blood glucose), reagents, calibrators |
| Cardiovascular | 166 | 13.6% | Coronary guide wires, vascular catheters, vascular closure systems |
| General Hospital | 160 | 13.1% | Infusion pumps (Plum, LifeCare), administration sets, IV accessories |
| Clinical Toxicology | 129 | 10.6% | Drugs-of-abuse testing assays, toxicology analyzers |
| Microbiology | 105 | 8.6% | Infectious disease assays (HIV, Hep C, influenza), molecular PCR assays |
| Hematology | 76 | 6.2% | Automated cell counters, coagulation instruments, hematology reagents |
| Gastroenterology, Urology | 43 | 3.5% | Biliary catheters, enteral feeding pumps, gastrointestinal tubes |
| Other Specialties | 119 | 9.9% | Dental diagnostics, anesthesiology tubes, diagnostic software |
| Total Active Clearances | 1,218 | 100.0% |
Detailed Product Code Directory: 510(k) Leaderboard
The table below breaks down the top active 510(k) product codes held by Abbott, demonstrating their focus in general hospital hardware and clinical laboratory tests:
| Product Code | Specialty | Regulatory Classification | Device Description | Key Brand Families | Active Clearances |
|---|---|---|---|---|---|
| FRN | General Hospital | Class II (21 CFR 880.5725) | Infusion Pump | Plum, LifeCare, GemStar pump lines | 69 |
| FPA | General Hospital | Class II (21 CFR 880.5440) | Intravascular Administration Set | Infusion sets, pump accessories | 31 |
| NBW | Clinical Chemistry | Class II (21 CFR 862.1345) | Blood Glucose Test System (OTC) | FreeStyle Libre sensors and readers | 31 |
| GKZ | Hematology | Class II (21 CFR 864.5220) | Automated Differential Cell Counter | CELL-DYN hematology systems | 30 |
| DQX | Cardiovascular | Class II (21 CFR 870.1280) | Catheter Guide Wire | Hi-Torque, vascular guide wires | 25 |
| JJE | Clinical Chemistry | Class II (21 CFR 862.2160) | Discrete Photometric Chemistry Analyzer | Architect, Alinity diagnostic systems | 24 |
| KNT | Gastroenterology | Class II (21 CFR 876.5980) | Gastrointestinal Tubes and Accessories | Enteral feeding tubes, nutrition sets | 22 |
| LIT | Cardiovascular | Class II (21 CFR 870.1250) | Peripheral Transluminal Angioplasty Catheter | Dilation balloons, access catheters | 18 |
| MIM | Clinical Chemistry | Class II (21 CFR 862.1660) | Quality Control Material (Assayed/Unassayed) | Multichem clinical QC lines | 17 |
| CHL | Clinical Chemistry | Class II (21 CFR 862.1120) | Blood Gases (Pco2, Po2) and Blood Ph | i-STAT cartridge systems | 16 |
Focus on Core 510(k) Product Categories
- FRN (Infusion Pumps): Infusion pumps are critical hospital hardware for delivering medications, nutrients, and fluids. Abbott's Plum 360 systems are cleared under this category. Regulatory audits focus heavily on software controls to prevent dosing errors and wireless integration security.
- NBW (OTC Blood Glucose Systems): The FreeStyle Libre series is cleared under this pathway. Unlike clinical lab instruments, these systems are used by patients at home, requiring extensive usability and human factors testing to ensure patients can read and act on glucose trends safely.
- GKZ (Hematology Cell Counters): CELL-DYN automated analyzers process blood specimens to deliver complete blood counts (CBC). Key clearance parameters focus on verification of dilution accuracy, cellular differentiation gating algorithms, and correlation statistics against reference microscopy.
Premarket Approval (PMA) Portfolio: Defibrillators, Diagnostics, and Ventricular Support
Abbott holds 5,617 PMA approvals and supplements, reflecting a major Class III regulatory presence. The company's PMA portfolio was significantly expanded by the acquisition of St. Jude Medical (bringing a massive cardiac rhythm management and electrophysiology portfolio) and Thoratec (ventricular assist systems), alongside its own diagnostics business (high-risk microbiology screening assays).
Detailed PMA Product Code Directory
The table below breaks down the high-risk Class III categories that dominate Abbott's PMA approvals:
| Product Code | Specialty | Regulatory Classification | Device Description | Key Brand Families | Active PMA Filings |
|---|---|---|---|---|---|
| NIK | Cardiovascular | Class III (21 CFR 870.3610) | CRT-D Defibrillator | Quadra, Claria, Gallant CRT-D | 489 |
| NVZ | Cardiovascular | Class III (21 CFR 870.3610) | Pulse Generator, Permanent, Implantable | Assurity, Azure pacing generators | 385 |
| LWS | Cardiovascular | Class III (21 CFR 870.3610) | Implantable Cardioverter Defibrillator | Fortify, Gallant ICD families | 355 |
| LOM | Microbiology | Class III (21 CFR 866.3480) | Hepatitis B Diagnostic Assay | Architect / Alinity HBV Assays | 293 |
| DSQ | Cardiovascular | Class III (21 CFR 870.3535) | Ventricular (Assist) Bypass | HeartMate II and HeartMate 3 LVADs | 275 |
| NVY | Cardiovascular | Class III (21 CFR 870.3680) | Permanent Defibrillator Electrodes | Durata, Optisure defibrillation leads | 242 |
| NVW | Cardiovascular | Class III (21 CFR 870.3680) | Pacemaker Electrode | Tendril pacing lead families | 188 |
| MFA | Cardiovascular | Class III (21 CFR 870.1250) | Laser Angioplasty / Lead Extraction | Lead extraction laser sheaths | 164 |
| LOK | Clinical Chemistry | Class III (21 CFR 862.1660) | AFP Tumor Marker Assay | Laboratory tumor screening tests | 112 |
| MUE | Radiology | Class III (21 CFR 892.1715) | Full Field Digital Mammography System | Legacy mammography lines | 94 |
Major Clinical Trials and PMA Approvals
Abbott's highest-risk Class III device clearances are supported by major, randomized clinical trials that establish safety profiles and mortality outcomes:
MOMENTUM 3 Trial (HeartMate 3 LVAD)
The HeartMate 3 Left Ventricular Assist Device (LVAD) is designed for patients with advanced, refractory left ventricular heart failure as bridge-to-transplant or destination therapy.
- Clinical Evidence: The PMA approval of the HeartMate 3 system was supported by the MOMENTUM 3 trial (1,028 patients), a randomized trial comparing HeartMate 3 against HeartMate II. The primary endpoint was survival free of disabling stroke or reoperation to replace/remove the device at 2 years. HeartMate 3 demonstrated a superior success rate of 81.2% compared to 71.2% for HeartMate II. Most importantly, the trial showed that HeartMate 3 virtually eliminated pump thrombosis, a critical clinical risk for previous generation pumps.
COAPT Trial (MitraClip System)
MitraClip is a transcatheter edge-to-edge repair (TEER) system cleared to treat patients with moderate-to-severe functional mitral regurgitation.
- Clinical Evidence: The PMA filings for MitraClip were backed by the COAPT trial (614 patients). The study compared MitraClip plus guideline-directed medical therapy (GDMT) against GDMT alone. The trial showed a 51.8% reduction in heart failure hospitalizations and a 38% reduction in all-cause mortality at 2 years. These results supported expanded PMA clearances for the G4 implant and subsequent clip size variations.
CardioMEMS HF System
CardioMEMS is an implantable pulmonary artery pressure sensor that provides daily hemodynamics measurements to guide medication adjustments remotely.
- Clinical Evidence: The CardioMEMS PMA approvals were supported by clinical trials showing a 28% reduction in heart failure hospitalizations at 6 months by allowing early medication titration based on pressure trends before clinical symptoms appear.
Specialty Highlight: Rapid Diagnostics and Point of Care (POC)
- i-STAT Handheld System: Unlike high-throughput laboratory chemistry analyzers that require plasma separation and central processing, Abbott's i-STAT system utilizes disposable cartridge arrays to perform blood gas, electrolyte, and coagulation testing in minutes at the bedside. Cleared under the 510(k) pathway, these point-of-care systems are evaluated on their sensor precision, cart-reader calibration control, and correlation statistics against central laboratory reference instruments. Sourcing audits focus heavily on cartridge storage controls (refrigeration requirements) and electronic quality testing (eQT) protocols.
- BinaxNOW Test Cards: Stemming from the Alere acquisition, these rapid lateral flow diagnostic cards are cleared under the microbiology 510(k) pathway for infectious diseases like influenza, RSV, and streptococcal pharyngitis, using visual or automated reader controls to verify result lines.
FDA Recalls and Safety Signals: Trends and Analysis
As of June 2026, FDA records associate 909 recalls with Abbott. This recall count reflects the diversity of Abbott's business, with safety alerts and field corrections distributed across clinical chemistry analyzers, hematology instruments, glucose monitoring sensors, and cardiovascular implants.
Annual Recall Trends (2020–2026)
Analyzing the year of initiation for Abbott's recall records highlights the impact of product quality improvements and regulatory reporting:
| Year | Recall Volume | Core Product Lines Affected | Strategic Context & Regulatory Rationale |
|---|---|---|---|
| 2020 | 31 | Infusion pumps, clinical toxicology reagents | Software pump anomalies, reagent calibration drift, labeling issues. |
| 2021 | 48 | Alinity diagnostic systems, pacing leads | Pipette alignment faults, lead insulation breaches, software connectivity bugs. |
| 2022 | 36 | HeartMate II / 3 LVAD controllers, guide wires | Controller backup battery faults, guide wire core cracks, packaging damage. |
| 2023 | 42 | CardioMEMS monitoring software, defibrillators | Software calibration errors, defibrillator battery depletion, connector faults. |
| 2024 | 87 | Clinical chemistry analyzers, glucose monitors | Spiked recall volume; analyzer reagent sensor updates, glucose app software patches. |
| 2025 | 104 | FreeStyle Libre 3 sensors, TactiFlex ablation catheters | CGM sensor calibration errors, catheter tip detachment risks, software patches. |
| 2026 (Part) | 28 | FreeStyle Libre 3 sensor disposal, analyzer software | CGM sensor exchange guidelines, analyzer communication software updates. |
Recall Distribution by Product Code
An analysis of Abbott's recall registrations by product code reveals that gastrointestinal tubes and clinical analyzers represent the highest frequency of recalls:
| Rank | Product Code | Device Category | Number of Recalls | Primary Recall Root Causes |
|---|---|---|---|---|
| 1 | KNT | Gastrointestinal Tube | 84 | Feeding tube connector cracks, balloon inflation valve leaks, labeling errors |
| 2 | JJE | Clinical Chemistry Analyzer | 74 | Analyzer software interface bugs, sample barcode reading errors, reagent leaks |
| 3 | GKZ | Hematology Cell Counter | 52 | Cell counter software drift, optical sensor misalignment, calibration errors |
| 4 | NBW | Blood Glucose Test System | 35 | CGM sensor calibration errors, incorrect low glucose readings, mobile app bugs |
| 5 | CHL | Blood Gas Electrode | 31 | Cartridge sensor calibration drift, electrode noise interference, package damage |
Recent 2025–2026 Class I Recall Case Studies
Abbott has managed two high-profile Class I recalls (indicating a risk of serious injury or death) in the 2025–2026 period:
- FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors (Early 2026): The FDA classified the recall of certain lots of Abbott's FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensors as Class I. The affected sensors could provide glucose readings that are lower than actual blood glucose levels. If unrecognized, these inaccurate low readings could lead users to make inappropriate treatment decisions (such as skipping insulin doses or consuming unnecessary carbohydrates), presenting a risk of severe hypoglycemia or diabetic ketoacidosis. The issue was associated with 860 reports of serious injury and seven deaths as of January 7, 2026. Abbott provided free replacement sensors, and users could verify their serial numbers at www.freestylecheck.com.
- TactiFlex Sensor Enabled Ablation Catheter (October 2025): The FDA posted a Class I recall for the TactiFlex Sensor Enabled Ablation Catheter. Abbott identified a limited number of catheter tip detachment events that occurred during the removal of the catheter from its packaging. A detached tip during navigation could lead to embolism, vascular damage, or cardiac tamponade. Abbott advised clinicians to inspect the catheter and packaging prior to use and handle the catheter carefully during setup.
Notable Historical Recalls and Safety Bulletins
- HeartMate 3 LVAD Outflow Graft Occlusion (2024): In early 2024, the FDA classified an advisory regarding HeartMate 3 Left Ventricular Assist Systems as a Class I recall. The action addressed reports of outflow graft twisting and occlusion, which could restrict blood flow from the pump and trigger low-flow alarms. This correction did not involve explanting the devices but required physicians to monitor patients for graft twisting using echocardiography or CT angiography.
- Assurity and Endurity Pacemaker Moisture Recalls (2022): Abbott recalled specific Assurity and Endurity pacemakers due to risk of moisture ingress into the pulse generator header, which could cause electrical shorts and premature battery depletion. This led to a manufacturing process change to improve the hermetic seal of the CRM header.
- Alinity m SARS-CoV-2 Assay Software Updates (2021): A Class I recall was issued for software driving the Alinity m molecular diagnostic system following reports that the system could produce false-positive results due to software processing delays, resolved via remote firmware updates.
Sub-tier Supplier and CDMO Quality Controls
Abbott's dual diagnostics and devices footprint requires highly specialized supplier quality controls:
- Diagnostic Reagent CDMOs: Sourcing raw antibodies, enzymes, and latex particles for immunoassay reagents requires audited sub-tier suppliers. Abbott Diagnostics verifies chemical purity, lot-to-lot bridging stability (to prevent signal drift on Architect systems), and compliance with ISO 13485 guidelines. Sourcing contracts dictate rigorous validation testing before any raw biological materials are introduced into high-volume manufacturing lines.
- Polymer and Balloon Extrusion: For vascular catheters (Temecula facility), catheter sheaths are extruded from medical-grade polymers. Abbott audits extrusion vendors to ensure wall thickness consistency and pull-strength tolerances, preventing catheter hub leaks or tip separations during clinical navigation.
- Sterile Tyvek Packaging: Packaging barrier integrity is verified via lot-specific dye penetration and seal strength testing. Sourcing agreements require suppliers to verify compliance with ISO 11607 packaging standards, ensuring diagnostic tests and sterile catheters remain clinical-ready.
Cybersecurity and Software Bill of Materials (SBOM) Compliance
In the era of connected health, cybersecurity is vital for devices transmitting patient data:
- Software Bill of Materials (SBOM): Abbott maintains comprehensive SBOMs for connected platforms, including the FreeStyle Libre mobile apps, Merlin.net patient care portals, and Alinity laboratory software. Sourcing teams can audit these SBOM registries to identify vulnerability risks in third-party communications or database libraries.
- Connected Device Vulnerabilities: The PSIRT coordinates incident response protocols, issuing firmware patches to address security gaps in telemetry transmitters or cardiac monitors, published as CVD safety alerts.
- Network Integration Auditing: procurement audits verify MDS2 compliance, checking encryption parameters for data-in-transit, user login access limits, and system logging capabilities.
European MDR and IVDR Transition Impact
The simultaneous implementation of the European Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has significantly impacted Abbott's European operations:
- IVDR Reagent Transitions: Under the IVDR (Regulation 2017/746), in-vitro diagnostic assays require far more technical documentation and clinical evidence. Abbott has prioritised high-volume clinical chemistry and microbiology reagents at its Wiesbaden, Germany facility, while rationalising low-volume specialty assays to manage high certification costs.
- Notified Body Bottlenecks: Coordination with European Notified Bodies is coordinated through European logistics hubs like Heerlen. Abbott has leveraged transition timelines to prevent diagnostic reagent supply shortfalls during documentation reviews.
Sourcing Decision Guide: Hospital Sourcing Matrix
Clinical engineering and laboratory value-analysis committees (VAT) should use the following decision matrix when auditing Abbott as a primary vendor:
[Abbott Footprint Audit Workflow]
│
┌──────────────────────┴──────────────────────┐
(Diagnostics Division) (Medical Devices CRM/Vascular)
│ │
Verify reagent batch warning history Verify specific PMA supplement history
│ │
Audit site-specific warning history Audit site-specific warning history
(e.g., Wiesbaden Chemistry vs. Lake Forest) (e.g., Sylmar pacemakers vs. Temecula Catheters)
│ │
┌─────────────┴─────────────┐ │
│ Monitor Libre sensor │ │
│ replacement portal status │ │
└─────────────┬─────────────┘ │
└──────────────────────┬──────────────────────┘
▼
Define standard uptime SLAs
(Exclude remote software patches)
Sourcing Decision Matrix:
- Laboratory Diagnostics & Reagents (Diagnostics Division):
- Audit Objective: Verify reagent batch consistency and instrument software stability.
- Decision Rule: Do not source immunoassay or clinical chemistry platforms unless the contract guarantees a maximum 24-hour delivery window for replacement reagents in the event of a lot-specific recall.
- Contract SLA: Mandate analyzer uptime of at least 98.5%. Exclude scheduled calibration or software updates from calculated downtime.
- Diabetes Care & CGMs (Diabetes Division):
- Audit Objective: Monitor the Libre safety verification portal status.
- Decision Rule: Ensure the vendor provides a dedicated patient-support API or portal integration to automatically notify the hospital's clinical team of any recalled sensor serial numbers assigned to patients.
- Contract SLA: Implement a zero-cost replacement policy for all sensors returned due to calibration errors or recall notices.
- Implantable Pacemakers & Assist Devices (Cardiovascular CRM/VAD):
- Audit Objective: Verify mechanical failure and out-of-box defect rates for HeartMate and TactiFlex platforms.
- Decision Rule: Do not implant catheters or LVAD components unless packaging integrity and sterileness have been visually verified in the preparation suite.
- Contract SLA: Require the vendor to provide on-site clinical specialists for all ventricular assist device setup and training at no additional fee.
Establishment Registrations and Global Manufacturing Footprint
To distribute medical devices and diagnostics in the United States, manufacturers must register their facilities and list all devices processed there. Abbott has 2,393 active establishment registration and device listings associated with its operating facilities.
Analyzing Abbott's listings by city reveals its primary manufacturing, R&D, and logistics hubs:
- Lake Forest, Illinois, USA (436 listings): Abbott's global headquarters for its Diagnostics division. This facility serves as a primary center for R&D, clinical chemistry instrument design, and diagnostic software engineering.
- Wiesbaden, Germany (264 listings): Abbott's largest European diagnostics manufacturing site. This facility is a global hub for manufacturing diagnostic reagents, immunoassay assays, and clinical chemistry consumables.
- Temecula, California, USA (131 listings): A major manufacturing site for Abbott's Cardiovascular business, specializing in vascular closure devices (Perclose), catheters, and guide wires.
- Sylmar, California, USA (124 listings): A key manufacturing and R&D site for Abbott's Cardiac Rhythm Management division, focusing on pacemakers and implantable cardioverter defibrillators.
- Heerlen, Limburg, Netherlands (116 listings): Abbott's primary European logistics and distribution center, coordinating the supply chain for diagnostics and medical devices across Europe.
Abbott Global Manufacturing Concentration
The geographic distribution of Abbott's listings reveals a balanced model that combines high-volume diagnostic manufacturing in Germany and the US with vascular and pacing hubs in California:
| Region | Listing Count | Percentage of Listings | Core Capabilities |
|---|---|---|---|
| United States (Lake Forest, Temecula, Sylmar) | 1,291 | 53.9% | Corporate administration, diagnostics R&D, cardiovascular & pacing manufacturing |
| Germany (Wiesbaden) | 264 | 11.0% | Diagnostic reagents, immunoassay assays, consumables manufacturing |
| Netherlands (Heerlen) | 116 | 4.8% | European logistics, distribution, supply chain management |
| Other Facilities (Sligo, Ireland; Singapore, etc.) | 722 | 30.3% | Point-of-care manufacturing, molecular diagnostics assembly, global depots |
| Total Listings | 2,393 | 100.0% |
How Abbott Compares With Peers
Abbott's regulatory footprint is best understood alongside its medical device industry peers. The table below places Abbott against major competitors across key FDA database metrics:
| Regulatory Metric | Medtronic | Boston Scientific | Abbott | GE HealthCare | Siemens Healthineers | Philips |
|---|---|---|---|---|---|---|
| Active 510(k) clearances | 1,597 | 864 | 1,218 | 1,680 | 1,573 | 1,322 |
| PMA approvals / supplements | 12,805 | 6,725 | 5,617 | 95 | 540 | 350 |
| FDA-registered recalls | 1,897 | 1,340 | 909 | 1,490 | 2,042 | 2,397 |
| Establishment / device listings | 7,855 | 2,399 | 2,393 | 5,512 | 4,114 | 5,180 |
| Leading 510(k) product code | NKB (Spine, 104) | LIT (Peripheral, 68) | FRN (Infusion Pump, 69) | IYN (Ultrasound, 179) | JAK (CT, 155) | LNH (MRI, 125) |
| PMA portfolio focus | ICDs & pacemakers (LWS, 1,463) | Pacemakers (LWP, 1,178) | CRT-D Defibrillators (NIK, 489) | Breast imaging (MUE, 37) | In-vitro diagnostics (LOM, 189) | Laser angioplasty (LPC, 124) |
Common Pitfalls When Auditing an Abbott Footprint
Vendor audits of Abbott's regulatory profile often fail due to predictable oversights:
- Failing to Segment Diagnostics vs. Devices: Abbott Diagnostics and Abbott Medical Devices operate under different quality systems and manufacturing facilities. When auditing Abbott, value-analysis teams must segment their evaluations by division (for example, auditing Wiesbaden for lab reagents vs. Sylmar for pacemakers).
- Overlooking Acquired Entities: Abbott's active database footprint includes legacy St. Jude Medical, Alere, and Thoratec submissions. Conducting searches solely under "Abbott Laboratories" will miss thousands of active clearances and PMA filings.
- Relying Solely on Raw Recall Totals: Because Abbott distributes millions of laboratory test cartridges and diagnostic reagents, a high recall count for clinical chemistry components (like product code JJE or CHL) represents a low relative risk per unit shipped compared to a recall of implantable ventricular assist devices.
- Neglecting European Logistics Channels: With Heerlen, Netherlands acting as Abbott's primary European logistics hub, supply continuity audits must evaluate European regulatory compliance and shipping stability affecting this critical Dutch warehouse.
Frequently Asked Questions (FAQ)
What is the most common medical specialty for Abbott 510(k) clearances?
Clinical Chemistry diagnostics represent the largest portion of Abbott's active 510(k) clearances, accounting for 420 clearances (34.5%), reflecting their leadership in laboratory instruments, assays, and continuous glucose monitoring.
Where are Abbott's primary FDA-registered diagnostics and device manufacturing plants?
Abbott's primary registered hubs by listing count are in Lake Forest, Illinois (436 listings for core diagnostics), Wiesbaden, Germany (264 listings for diagnostic assays and reagents), and Temecula, California (131 listings for cardiovascular catheters and closure devices).
How many FDA recalls are associated with Abbott?
As of June 2026, FDA records associate 909 recalls with Abbott. These are distributed across gastrointestinal feeding tubes, clinical chemistry analyzers, hematology systems, and continuous glucose sensors.
What was the reason for the Abbott FreeStyle Libre 3 Class I recall?
In early 2026, the FDA classified the recall of certain FreeStyle Libre 3 and Libre 3 Plus continuous glucose sensors as Class I because they could provide glucose readings that are lower than actual blood glucose levels. This could lead to incorrect treatment decisions, risking severe hypoglycemia or diabetic ketoacidosis.
How can patients verify if their FreeStyle Libre sensor is recalled?
Abbott provides a dedicated safety verification portal at www.freestylecheck.com where patients and healthcare providers can enter sensor serial numbers to check if their specific device is included in the recall.
Does Abbott Diagnostics operate under the same quality system as Abbott CRM?
No. Abbott Diagnostics (based in Lake Forest) and Abbott Medical Devices (based in Sylmar) operate under separate quality systems and FDA registration listings, necessitating distinct audits.
Are St. Jude pacemakers still covered under current Abbott listings?
Yes, legacy St. Jude CRM products (like Assurity pacemakers) are fully integrated into Abbott's active FDA database listings and post-market tracking systems.
What does product code FRN represent in Abbott's 510(k) library?
Product code FRN represents general-use volumetric infusion pumps (Class II, 21 CFR 880.5725). Many clearances under this code relate to legacy Hospira and nutrition systems that continue to support clinical wards.
How does the Wiesbaden site impact European diagnostics sourcing?
As Abbott's primary European immunoassay and clinical chemistry reagent facility, the Wiesbaden plant is critical for laboratory continuity, requiring tracking of local German audit histories and IVDR transitions.
What clinical trials support the HeartMate 3 LVAD approvals?
The HeartMate 3 system PMA approvals were supported by the MOMENTUM 3 trial, which demonstrated a significant improvement in survival free of disabling stroke or reoperation (81.2% success) and virtually eliminated pump thrombosis.
Educational Disclaimer
This regulatory dossier is provided for educational and informational purposes only. It is based on computed aggregates of public FDA database extracts from June 2026 and should not be construed as legal, regulatory, clinical, quality system, or reimbursement advice for any specific product, clinical protocol, or commercial transaction.